HCW Biologics Inc (NASDAQ: HCWB) has experienced a decline in its stock price by -4.48 compared to its previous closing price of 8.70. However, the company has seen a gain of 1.34% in its stock price over the last five trading days. globenewswire.com reported 2025-05-15 that MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2025.
Is It Worth Investing in HCW Biologics Inc (NASDAQ: HCWB) Right Now?
The stock has a 36-month beta value of 0.89. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HCWB is 1.05M, and at present, short sellers hold a 0.66% of that float. On May 23, 2025, the average trading volume of HCWB was 652.72K shares.
HCWB’s Market Performance
The stock of HCW Biologics Inc (HCWB) has seen a 1.34% increase in the past week, with a 4.79% rise in the past month, and a -46.73% fall in the past quarter. The volatility ratio for the week is 5.84%, and the volatility levels for the past 30 days are at 17.28% for HCWB. The simple moving average for the past 20 days is 7.04% for HCWB’s stock, with a -49.07% simple moving average for the past 200 days.
HCWB Trading at -11.04% from the 50-Day Moving Average
After a stumble in the market that brought HCWB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.76% of loss for the given period.
Volatility was left at 17.28%, however, over the last 30 days, the volatility rate increased by 5.84%, as shares surge +4.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.08% lower at present.
During the last 5 trading sessions, HCWB rose by +1.34%, which changed the moving average for the period of 200-days by -65.38% in comparison to the 20-day moving average, which settled at $7.76. In addition, HCW Biologics Inc saw -53.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HCWB starting from Wong Hing C, who purchase 8,054 shares at the price of $7.45 back on May 16 ’25. After this action, Wong Hing C now owns 501,911 shares of HCW Biologics Inc, valued at $60,002 using the latest closing price.
Winer Gary M, the Director of HCW Biologics Inc, purchase 1,342 shares at $7.45 during a trade that took place back on May 16 ’25, which means that Winer Gary M is holding 4,075 shares at $9,998 based on the most recent closing price.
Stock Fundamentals for HCWB
Current profitability levels for the company are sitting at:
- -16.57 for the present operating margin
- 0.24 for the gross margin
The net margin for HCW Biologics Inc stands at -17.13. The total capital return value is set at 27.96. Equity return is now at value -27725.80, with -87.29 for asset returns.
Based on HCW Biologics Inc (HCWB), the company’s capital structure generated -2.68 points at debt to capital in total, while cash flow to debt ratio is standing at -2.27. The debt to equity ratio resting at -0.73. The interest coverage ratio of the stock is -63.82.
Currently, EBITDA for the company is -27.68 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 15.68. The receivables turnover for the company is 16.52for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.07.
Conclusion
To sum up, HCW Biologics Inc (HCWB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
